N/A N=234 Supportive Care

LifeBio Memory Digital Reminiscence Platform

Dementia · Cognitive Impairment

Bottom Line

View on ClinicalTrials.gov: NCT04769466 ↗

Enrolled (actual)

234

Serious AEs

0.0%

Results posted

Oct 2025

Primary outcome: Primary: Change in Center for Epidemiological Studies Depression Scale (CES-D) From Baseline — 7.04; 6.09 score on a scale — p=0.020

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: LifeBio Memory (Other)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Benjamin Rose Institute on Aging
Primary completion: Mar 2024

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Center for Epidemiological Studies Depression Scale (CES-D) From Baseline	7.04; 6.09	0.020 sig
PRIMARY Change in Satisfaction With Care in the Nursing Home Scale From Baseline	6.95; 6.84	0.223
PRIMARY Change in Quality of Life Alzheimer's Disease (QoL-AD) From Baseline	35.60; 34.70	0.036 sig
PRIMARY Change in Cohen-Mansfield Agitation Inventory (CMAI) - Short Form From Baseline	17.13; 16.23	0.131
PRIMARY Change in Staff Attitudes Towards Residents Scale From Baseline	16.43; 16.32	0.351
PRIMARY Change in Individualized Care Instrument (ICI) Subscale - Knowing the Person - From Baseline	41.09; 42.15	0.08
PRIMARY Change in The UCLA 3-Item Loneliness Scale From Baseline	4.50; 4.46	0.400
PRIMARY Resident Satisfaction With the LifeBio Memory Program	6.42	—
PRIMARY Change in Perceived Importance of Life Story Work Among Staff	13.32; 12.79	0.011 sig
PRIMARY Staff Satisfaction With LifeBio Memory Program	33.57	—
PRIMARY Change in Sense of Competence in Dementia Care Staff (SCIDS) Scale From Baseline	55.35; 55.48	0.459
PRIMARY Change in Person-Centered Care Assessment Tool [Sub-Scales I and II] From Baseline	39.70; 37.96	0.033 sig
PRIMARY Change in Direct Care Worker Job Satisfaction Scale From Baseline	27.66; 26.85	0.103
PRIMARY Change in Individualized Care Instrument (ICI) Subscale - Resident Autonomy Subscale - From Baseline	58.46; 58.44	0.494
PRIMARY Change in Individualized Care Instrument (ICI) Subscale - Staff and Resident Communication Subscale - From Baseline	20.72; 21.15	0.214
PRIMARY Change in Individualized Care Instrument (ICI) Subscale - Staff to Staff Communication Subscale - From Baseline	27.02; 26.30	0.199
PRIMARY Staff Perceptions About the Feasibility of the LifeBio Memory Program Protocol	26.26	—
SECONDARY Change in Mini Mental Status Examination (MMSE) From Baseline	21.07; 19.72	—
SECONDARY Change in Staff Adequate Knowledge of Residents' Care Preferences From Baseline	2.76; 3.54	<.001 sig
SECONDARY Change in Staff Adequate Knowledge of Residents' Life Stories From Baseline	2.68; 3.58	<.001 sig

Summary

Non-pharmacological interventions and person-centered care strategies are important elements of care for people with Alzheimer's disease and related dementias. Life story work, which uses written and oral life histories to elicit conversation and memories, is an effective intervention for individuals with dementia; however, because of the time-consuming nature of generating useful life story materials, has not been widely implemented in nursing homes and other care environments. LifeBio Inc. will develop an easy-to-use reminiscence therapy platform - LifeBio MemoryTM - with a novel machine-learning-based application that converts speech to text and generates life stories to serve as an interactive tool to cultivate communication between people living with dementia and their family and caregivers.

Eligibility Criteria

Inclusion Criteria (Staff):

Work within a residential care facility participating in the study
Speak and read English
Able to provide own transportation to and from interviews with residents

Inclusion Criteria (Residents

Must reside within a participating residential care facility
Must be at least 55 years of Age
Must speak and read English
Have a Dementia diagnosis
Have a Score of at least 15 on the Mini Mental State Examination

Exclusion Criteria (Residents)

Residents will be excluded from the study if they show signs of rapid cognitive decline or physical deterioration over the last 6 months, as evidence by information gained during screening.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04769466). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.